|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, September 21, 2017 ) Description
“Malignant Glioma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Malignant Glioma Report is to understand the market and pipeline status of the drugs around the Malignant Glioma to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies.
The Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Malignant Glioma. While the leading brands, companies and chemicals are considered thoroughly, report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.
Get a PDF Sample of Report at: http://www.orbisresearch.com/contacts/request-sample/232504 .
SCOPE:
A snapshot of the global Market and Phase III therapeutics scenario for Malignant Glioma.
A review of the marketed products under prescription for Malignant Glioma, regulatory information and marketing status.
Coverage of global patent coverage and detailed commentaries on the US patent challenges.
Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
Product profiles for marketed products for Malignant Glioma with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
Coverage of API Manufacturers for Malignant Glioma drugs in the United States, Europe and Asian Regions with location details.
Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Malignant Glioma drugs.
Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Malignant Glioma drugs.
Coverage of Malignant Glioma Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
Key discontinued Marketed products.
Global Sales Figure to 2018.
To Browse the Entire Report, Visit : http://www.orbisresearch.com/reports/index/malignant-glioma-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2017 .
Reasons to buy
Evaluate the marketing status and exclusivity details of Malignant Glioma key products to exploit opportunities for generic drug development opportunities.
Identify and understand important and diverse types of therapeutics under Phase III development for Malignant Glioma.
Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Malignant Glioma.
API intelligence over marketed drugs forMalignant Gliomaand gaining primary intelligence over active ingredients manufacturers across the globe.
API intelligence over leading Phase III Pipeline drugs.
Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
Understanding the scope of the Phase III Drugs with nil regulatory filings.
Understanding the chemical route of synthesis of approved drugs for Malignant Glioma.
Uncovering opportunities in the rapidly growing US market.
No. of Report Pages: 100
Place a Purchase Order for this Market Report at: http://www.orbisresearch.com/contact/purchase/232504 .
Some Points Of TOC:
Indication Overview
Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
Drugs Market Data and Forecasted Sales Figure-2018
Marketed Drugs for Malignant Glioma
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
Phase III Drugs for Malignant Glioma
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
Discontinued Drugs for Malignant Glioma
Appendix
Methodology
Consulting Services
Contact Us
Disclaimer
Got any Query? Feel free to ask us at : http://www.orbisresearch.com/contacts/enquiry-before-buying/232504 .
Orbis Research
Hector Costello
+1 (214) 884-6817
sales@orbisresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
